TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Rating of “Buy” from Brokerages

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) have earned an average recommendation of “Buy” from the nine analysts that are presently covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $11.79.

A number of research firms have recently commented on TLSI. Canaccord Genuity Group dropped their price objective on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Roth Mkm assumed coverage on shares of TriSalus Life Sciences in a research note on Monday, November 11th. They set a “buy” rating and a $11.00 price target on the stock. Roth Capital upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Northland Capmk upgraded TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Finally, Northland Securities initiated coverage on TriSalus Life Sciences in a report on Friday, October 25th. They issued an “outperform” rating and a $12.50 target price on the stock.

Insider Buying and Selling at TriSalus Life Sciences

In other news, major shareholder Equity Ab Frankenius acquired 62,972 shares of the stock in a transaction on Tuesday, December 17th. The stock was bought at an average price of $3.97 per share, with a total value of $249,998.84. Following the completion of the transaction, the insider now directly owns 6,230,748 shares of the company’s stock, valued at $24,736,069.56. The trade was a 1.02 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders have purchased 70,012 shares of company stock valued at $281,235 over the last three months. 32.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Highbridge Capital Management LLC acquired a new position in TriSalus Life Sciences in the 2nd quarter worth $1,184,000. Duquesne Family Office LLC increased its position in shares of TriSalus Life Sciences by 35.1% during the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after acquiring an additional 110,966 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after acquiring an additional 62,542 shares in the last quarter. MSD Partners L.P. purchased a new position in TriSalus Life Sciences in the third quarter valued at about $184,000. Finally, Vestcor Inc acquired a new stake in TriSalus Life Sciences during the 3rd quarter valued at approximately $108,000. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

TriSalus Life Sciences Trading Down 7.2 %

TriSalus Life Sciences stock opened at $4.78 on Thursday. The stock has a fifty day moving average price of $4.32 and a 200 day moving average price of $4.81. TriSalus Life Sciences has a 52 week low of $3.50 and a 52 week high of $10.42. The firm has a market capitalization of $145.76 million, a P/E ratio of -1.92 and a beta of 0.51.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.